Adaptimmune

Adaptimmune is a clinical-stage biopharmaceutical company developing engineered T cell receptor therapies targeting solid tumours.

The company's T-cell platform engineers T cell receptors with enhanced affinity for cancer-associated antigens, enabling immune recognition of tumour cells that evade conventional therapies.

Adaptimmune received FDA approval for its lead therapy in synovial sarcoma in 2024, the first approved T cell therapy for a solid tumour.

The company is headquartered in Philadelphia with UK research operations at Milton Park.